WEB Second Phase 2 trial initiated from BioNTech's proprietary individualized mRNA-based cancer vaccine platform.
WEB MAINZ Germany October 19 2023 GLOBE NEWSWIRE BioNTech SE Nasdaq
WEB July 30 Reuters - COVID-19 vaccine maker BioNTech's 22UAyDE cancer drug candidate BNT111 showed
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine.
Der Impfstoffhersteller Biontech will mRNA-basierte Krebsimpfstoffe entwickeln die das Immunsystem.
Wie Biontech am Dienstag mitteilte zeigte eine Kombinationstherapie aus genetisch veränderten Immunzellen.
Comments